Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SLXN

Silexion Therapeutics Corp

Dec 13 • 11:31AM ET

3.36

Dollar change +0.02
Percentage change 0.59	%

Healthcare • Biotechnology • Israel • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.26	Insider Own	11.04%	Shs Outstand	0.43M	Perf Week	22.17%
Market Cap	5.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.38M	Perf Month	52.30%
Income	-0.52M	PEG	-	EPS next Q	-0.99	Inst Own	30.17%	Short Float	9.43%	Perf Quarter	-59.58%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.05	Perf Half Y	-96.62%
Book/sh	5.90	P/B	0.57	EPS next Y	-	ROA	-3.13%	Short Interest	0.04M	Perf Year	-96.28%
Cash/sh	3.71	P/C	0.91	EPS next 5Y	-	ROE	-3.78%	52W Range	1.86 - 122.02	Perf YTD	-96.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-20.64%	52W High	-97.25%	Beta	-0.08
Dividend TTM	-	Quick Ratio	1.75	Sales past 5Y	0.00%	Gross Margin	-	52W Low	80.33%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	1.75	EPS Y/Y TTM	-227.79%	Oper. Margin	-	RSI (14)	53.43	Volatility	14.46% 20.60%
Employees	-	Debt/Eq	1.32	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	9.00
Option/Short	No / No	LT Debt/Eq	0.00	EPS Q/Q	-1038.32%	Payout	0.00%	Rel Volume	0.20	Prev Close	3.34
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	794.77K	Price	3.36
SMA20	20.38%	SMA50	20.68%	SMA200	-94.38%	Trades		Volume	55,801	Change	0.59%

Dec-10-24 08:30AM	Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors (GlobeNewswire)
Nov-22-24 04:30PM	Silexion Therapeutics Announces 1-for-9 Reverse Share Split (GlobeNewswire)
Nov-20-24 08:30AM	Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +47.26%
Nov-14-24 08:30AM	Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (ACCESSWIRE) -8.73%
Oct-09-24 05:35PM	Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit (ACCESSWIRE) -11.93% -5.98%
06:45AM	Loading…
Oct-01-24 06:45AM	Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies (Business Wire) +5.90%
Sep-24-24 07:30AM	Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER in Non-Resectable Pancreatic Cancer (Business Wire) -16.28%
Sep-09-24 07:32AM	PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers (Business Wire) +11.61%
Sep-03-24 04:05PM	Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference (GlobeNewswire) -24.66% -10.98%
Aug-15-24 04:05PM	Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination (GlobeNewswire) -13.21% -79.39%

Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The company is headquartered in Modiin, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLXN

Silexion Therapeutics Corp

Upgrade your FINVIZ experience